Program Description
Despite advancements in acute care, stroke remains a leading cause of long-term disability. In the United States, approximately 800,000 individuals experience a stroke annually, of which nearly 25% are recurrent events. Current guidelines emphasize the TOAST classification to drive therapy selection and emphasize short-term dual antiplatelet therapy to prevent recurrence, though this approach targets the body’s primary clotting pathways and can significantly increase the risk of major hemorrhage. Emerging Factor XIa (FXIa) inhibitors represent a novel approach that targets the amplification phase of the coagulation cascade. This session will review the mechanistic differences between these pathways, equipping pharmacists to better navigate the transition to dual-pathway inhibition. Expert faculty will highlight tools to apply stroke classification systems for precise therapy selection and development of pharmacist-led strategies such as medication therapy management and adherence counseling to support pharmacists as essential antithrombotic stewards in stroke prevention and management.
Target
audience: Specialty
Pharmacists, Health-System Pharmacists
Type of activity: Application
Release date: June 17, 2026
Expiration date: June 17, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Differentiate non-cardioembolic subtypes using ischemic stroke pathophysiology and Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification to inform selection of evidence-based antithrombotic strategies for secondary prevention
- Explain the intrinsic and extrinsic coagulation pathways and how Factor XIa contributes to thrombosis formation
- Analyze recent efficacy and safety data pertaining to the use of emerging Factor XIa inhibitors in clinical practice
- Identify opportunities for pharmacists to support antithrombotic stewardship through medication therapy management, adherence monitoring, and counseling
Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP
Anticoagulation Stewardship Lead
PGY-2 Thrombosis and Hemostasis Management Residency Program Director
Department of Pharmaceutical Services
Sanford USD Medical Center
Clinical Professor
Department of Internal Medicine
University of South Dakota Sanford School of Medicine
Sioux Falls, SD
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10CEU) under the ACPE universal activity number 0290-0000-26-177-H01-P The activity is available for CE credit through June 17, 2027
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Michael P. Gulseth, PharmD, BCPS, FMSHP, FASHP, has no relevant financial relationships with ineligible companies to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational
purposes and do not constitute any form of professional advice or referral.
Discussions concerning drugs, dosages, and procedures may reflect the clinical
experience of the author(s) or be derived from the professional literature or
other sources and may suggest uses that are investigational in nature and not
approved by the labeling or indications. Participants are encouraged to refer
to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms